FirstWord

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:
  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Research Reports By FirstWord

Found 502 publications
Rheumatoid Arthritis [2017] US$ 8,145.00 Apr, 2017
The Future of Biobetters US$ 2,245.00 Apr, 2017
Biosimilars: US Payer Perspectives US$ 2,245.00 Apr, 2017
Market Access Impact (US) [HIV] US$ 5,145.00 Apr, 2017
NPS+ (US) [PsO] US$ 2,575.00 Apr, 2017
Market Access Impact (EU5) [HIV] US$ 5,145.00 Apr, 2017
NPS+ (EU5) [PsO] US$ 2,575.00 Apr, 2017
Market Access Impact (EU5) [PsO] US$ 5,145.00 Mar, 2017
Biosimilars in Emerging Markets US$ 2,245.00 Mar, 2017
NPS+ (EU5) [HIV] US$ 2,575.00 Mar, 2017
HNSCC: KOL Insight [2017] US$ 8,145.00 Mar, 2017
NPS+ (US) [HIV] US$ 2,575.00 Mar, 2017
Market Access Impact (US) [PsO] US$ 5,145.00 Mar, 2017
NPS+ (US) [RCC] US$ 2,575.00 Feb, 2017
NPS+ (EU5) [Parkinson's Disease] US$ 2,575.00 Feb, 2017
Market Access Impact (EU5) [Melanoma] US$ 5,145.00 Feb, 2017
NPS+ (US) [Parkinson's Disease] US$ 2,575.00 Feb, 2017
Targeted Therapies in Asthma [2017] US$ 8,145.00 Feb, 2017
NPS+ (EU5) [Cancer Pain] US$ 2,575.00 Feb, 2017
Cystic Fibrosis: KOL Insight [2017] US$ 8,145.00 Feb, 2017
NPS+ (US) [Cancer Pain] US$ 2,575.00 Feb, 2017
AML: KOL Insight [2017] US$ 8,145.00 Feb, 2017
Market Access Impact (US) [Melanoma] US$ 5,145.00 Feb, 2017
NPS+ (EU5) [RCC] US$ 2,575.00 Feb, 2017
The Future of Medical Affairs US$ 695.00 Dec, 2016
Colorectal Cancer KOL Insight 2016 US$ 7,900.00 Oct, 2016
Market Access Impact: Myeloma (US) US$ 4,995.00 Oct, 2016
Market Access Impact: Myeloma (EU5) US$ 4,995.00 Oct, 2016
Hepatitis C: KOL Insight US$ 7,900.00 Sep, 2016
1 2 3 4 5 ... 11
Skip to top

Analytics, News & Press-Releases by FirstWord